Exelixis, Inc. EXEL

Company Overview

Exelixis, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of oncology therapeutics. The company operates primarily within the biopharmaceutical and precision oncology industries, with a strategic emphasis on targeted cancer therapies and combination treatment regimens. Exelixis generates the majority of its revenue from sales of cabozantinib-based products, particularly CABOMETYX, which is approved for multiple cancer indications including renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also earns collaboration and licensing revenue through partnerships with larger pharmaceutical companies.

Exelixis was founded in 1994 and initially focused on genomics and drug discovery technologies before transitioning toward oncology therapeutics development. Its commercial transformation accelerated following the successful development and approval of cabozantinib, a tyrosine kinase inhibitor targeting MET, VEGFR, and related pathways implicated in tumor growth and metastasis. The company has positioned itself as a specialized oncology innovator with expertise in targeted therapies and clinical development in difficult-to-treat cancers.

Business Operations

Exelixis primarily operates through a single reportable business focused on oncology therapeutics. Its principal commercial assets include CABOMETYX, COMETRIQ, and pipeline immuno-oncology and targeted therapy candidates. Revenue is generated through product sales, licensing agreements, milestone payments, and collaboration arrangements. The company’s operations are concentrated in the United States, though its products are marketed internationally through strategic partnerships and licensing arrangements with companies including Ipsen and Takeda Pharmaceutical Company. Exelixis retains commercialization rights for CABOMETYX in the U.S., while partners manage commercialization in many overseas markets.

The company controls significant intellectual property related to kinase inhibition technologies and maintains extensive clinical development infrastructure supporting late-stage oncology trials. Exelixis has established collaborations with major pharmaceutical firms including Bristol Myers Squibb, Merck & Co., Roche, and Pfizer to evaluate cabozantinib in combination with immunotherapies and other cancer treatments. Its operational strategy relies heavily on advancing clinical indications for existing compounds while expanding its internally developed oncology pipeline.

Strategic Position & Investments

Exelixis has focused its strategic direction on expanding its oncology franchise beyond cabozantinib through internal drug development, external licensing, and targeted acquisitions. The company has invested in next-generation cancer therapeutics including antibody-drug conjugates, targeted protein degraders, and immunomodulatory therapies. Recent pipeline programs have included compounds such as zanzalintinib and XB002, reflecting an effort to diversify future revenue streams beyond its flagship product portfolio.

The company has also pursued strategic acquisitions and licensing arrangements to strengthen its development pipeline. Exelixis acquired XIUS-bcg assets and entered collaborations aimed at expanding capabilities in biologics and precision oncology. Its investment strategy emphasizes clinically validated oncology targets and combination therapy approaches, particularly in solid tumors. Public filings and investor materials indicate that management continues to prioritize business development opportunities that complement its existing oncology expertise while maintaining a strong cash position to support research and development activities.

Geographic Footprint

Exelixis is headquartered in Alameda, California, and primarily operates in the United States, where it conducts most commercial, research, and administrative activities. Through international licensing and commercialization agreements, the company maintains market exposure across Europe, Asia-Pacific, and other global oncology markets. CABOMETYX and related products have achieved approvals in numerous jurisdictions outside the U.S. through partner-led commercialization efforts.

The company’s international presence is largely driven by collaborations with Ipsen in regions outside the U.S. and Japan, and with Takeda Pharmaceutical Company in Japan. These partnerships provide Exelixis with royalty and milestone revenue while extending product penetration into major oncology treatment markets globally. Clinical development programs also involve multinational trial networks spanning North America, Europe, and Asia.

Leadership & Governance

Exelixis is led by an executive team with significant experience in biotechnology commercialization, oncology drug development, and pharmaceutical operations. The company’s leadership strategy has emphasized disciplined capital allocation, lifecycle management of cabozantinib-based therapies, and expansion of the oncology pipeline through both internal innovation and external partnerships. Governance practices are overseen by a board of directors with backgrounds in biotechnology, medicine, and finance.

Key executives include:

• Michael M. Morrissey – President and Chief Executive Officer
• Dana Aftab – Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer
• Jeffrey Hessekiel – Executive Vice President and Chief Commercial Officer
• Chris Senner – Executive Vice President and Chief Financial Officer
• Peter Lamb – Executive Vice President, Scientific Strategy and Chief Scientific Officer
• Patrick J. Haley – Executive Vice President and General Counsel

The company’s leadership has consistently communicated a strategy centered on long-term oncology portfolio expansion, maximizing the commercial potential of approved therapies, and advancing differentiated clinical assets through late-stage development.